Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Grigg

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 3, 2014
Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remissionJennifer L Holter Chakrabarty, Morel Rubinger, Jennifer Le-Rademacher, et al.
Leukemia & Lymphoma|November 23, 2019
Treatment practice and outcomes in <i>FLT3-</i>mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitalsChong C Chua, Andrew Grigg, Jasmine Singh, et al.
British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.
Blood Advances|June 14, 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE studyCarol Moreno, Isabelle G Solman, Constantine S Tam, et al.
European Journal of Clinical Pharmacology|October 7, 2022
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myelomaChrista Ellen Nath, Andrew Grigg, Sebastian P A Rosser, et al.
Hemasphere|November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AMLAnthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
Haematologica|December 22, 2018
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
Blood|March 15, 2003
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced ageLinda Mileshkin, James J Biagi, Paul Mitchell, et al.
Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 3, 2014
Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remissionJennifer L Holter Chakrabarty, Morel Rubinger, Jennifer Le-Rademacher, et al.
Leukemia & Lymphoma|November 23, 2019
Treatment practice and outcomes in <i>FLT3-</i>mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitalsChong C Chua, Andrew Grigg, Jasmine Singh, et al.
British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.
Blood Advances|June 14, 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE studyCarol Moreno, Isabelle G Solman, Constantine S Tam, et al.
European Journal of Clinical Pharmacology|October 7, 2022
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myelomaChrista Ellen Nath, Andrew Grigg, Sebastian P A Rosser, et al.
Hemasphere|November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AMLAnthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
Haematologica|December 22, 2018
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
Blood|March 15, 2003
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced ageLinda Mileshkin, James J Biagi, Paul Mitchell, et al.
Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.
Pageof 14